Mer­ck re­ports an­oth­er fail­ure for Keytru­da-Lyn­parza com­bo in non-small cell lung can­cer

Last year
R&D
Pharma

VML Health part­ners on new key opin­ion leader man­age­ment for bio­phar­mas

Last year
Pharma
Marketing

GSK joins Boehringer and As­traZeneca in cap­ping out-of-pock­et costs for in­halers

Last year
Pharma

Medicare and Med­ic­aid open cov­er­age of an­ti-obe­si­ty drugs for heart pa­tients

Last year
Pharma

De­spite Phase 3 win, Roche says rare au­toim­mune drug did­n't meet ex­pec­ta­tions

Last year
R&D

In­nate ends Ph1b in pe­riph­er­al T cell lym­phoma; Lay­offs at NextCure

Last year
News Briefing

Catal­ent cuts 130 work­ers in In­di­ana; Mer­ck KGaA to build in South Ko­rea; Schott ex­pands US foot­print

Last year
Manufacturing

Sen­ate opens probe in­to how high-risk re­search pos­es na­tion­al se­cu­ri­ty threats

Last year
China
Pharma

Gal­der­ma tar­gets one of this year's biggest Eu­ro­pean IPOs with top-of-the-range share price

Last year
Financing
R&D

Bound­less Bio seeks $88M in IPO as it runs two Ph1 can­cer tri­als

Last year
Financing
Startups

For­mer Prometheus ex­ecs raise $400M for pre­ci­sion im­munol­o­gy start­up: 'The band is back to­geth­er'

Last year
Financing
Startups

Ex­clu­sive: ‘If you could hal­lu­ci­nate a pro­tein’: Proflu­ent snags $35M for gen­er­a­tive AI mod­els

Last year
Financing
Startups

Where Google thinks gen­er­a­tive AI is head­ed in health­care

Last year
Health Tech

Bay­er's re­struc­tur­ing hits phar­ma lead­er­ship, shift­ing about half of ex­ecs off top team

Last year
People
Pharma

FDA ap­proves Idor­sia’s high blood pres­sure drug for pa­tients who need oth­er op­tions

Last year
Pharma
FDA+

The Op­di­vo-Yer­voy com­bo from Bris­tol My­ers is work­ing to­ward ap­proval in first-line liv­er can­cer

Last year
R&D
Pharma

As­traZeneca de­buts Air­supra DTC cam­paign along with a first-ever tele­health op­tion

Last year
Pharma
Marketing

When can ob­ser­va­tion­al stud­ies sup­port a drug's ef­fec­tive­ness? FDA ex­plains in new draft guid­ance

Last year
FDA+

Ab­b­Vie inks deal with Parvus; Sofinno­va in­vests in Cure51

Last year
News Briefing

The megaround re­bound: Pri­vate biotechs rack up $100M+ fi­nanc­ings

Last year
Financing
Startups

David Bak­er’s lab shows gen­er­a­tive AI can de­sign an­ti­bod­ies. But are they good enough to be­come drugs?

Last year
R&D
AI

As fo­cus shifts to on­col­o­gy, BioN­Tech nabs No­var­tis ex­ec as chief com­mer­cial of­fi­cer

Last year
People
R&D

Lab­corp ex­pands Alzheimer’s blood tests for doc­tors and drug­mak­ers

Last year
R&D
Pharma

Ace­lyrin crew be­hind first thy­roid eye dis­ease med­i­cine builds its po­ten­tial com­peti­tor, with ear­ly da­ta to boast

Last year
R&D
First page Previous page 182183184185186187188 Next page Last page
A service from the Financial Times